Macroaxis Story

Macroaxis News
  
By Ellen Johnson

May 16, 2019

Today article will analyze 3 Healthcare isntruments to have in your portfolio in June 2019. I will specifically cover the following equities: Henry Schein, Danaher Corporation, and Edwards Lifesciences Corporation
The Top 3 Healthcare stocks to own in June 2019

This list of potential positions covers USA Equities from Healthcare industry as classified by Fama & French. Fama and French focuses on testing asset pricing under different economic assumptions in USA. Please note, we provide buy hold or sell recommendation only in the context of selected investment horizon assuming investor has average attitude towards taking risk. Please also consider using Portfolio Positions Ratings and Equity Ratings tools to further calibrate your research.


Henry Schein (HSIC)

The company has return on total asset (ROA) of 7.51 % which means that it generated profit of $7.51 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 15.68 % meaning that it created $15.68 on every $100 dollars invested by stockholders. The firm currently falls under 'Large-Cap' category with current market capitalization of 10.13B. Henry Schein retains regular Real Value of $122.04 per share. The prevalent price of the corporation is $68.89. At this time the corporation appears to be undervalued. Macroaxis calculates value of Henry Schein from evaluating the corporation fundamentals such as Return On Equity of 15.68%, Return On Asset of 7.51% and Current Valuation of 12.36B as well as inspecting its technical indicators and Probability Of Bankruptcy. In general, we encourage to acquire undervalued assets and to sell overvalued assets since at some point stocks prices and their ongoing real values will come together. Henry Schein competes with Patterson Companies, Microsoft, and Pfizer. Henry Schein, Inc. provides health care products and services to dental practitioners and laboratories, physician practices, government, institutional health care clinics, and other alternate care clinics worldwide. The company was founded in 1932 and is headquartered in Melville, New York. Henry Schein operates under Medical Distribution classification in USA and is traded on BATS Exchange. It employs 19000 people.

Danaher Corporation (DHR)

The company has Net Profit Margin of 12.04 % which may imply that it executes well on its competitive polices and has a good control over its expenditures and variable costs. This is very large. In the same way, it shows Net Operating Margin of 24.11 % which entails that for every 100 dollars of revenue it generated 0.24 of operating income. The firm currently falls under 'Large-Cap' category with total capitalization of 93.86B.
Total Debt
Danaher shows prevailing Real Value of $112.18 per share. The current price of the firm is $130.21. At this time the firm appears to be overvalued. Macroaxis computes value of Danaher from reviewing the firm fundamentals such as Shares Outstanding of 715.93M, Profit Margin of 12.04% and Current Valuation of 102.04B as well as analyzing its technical indicators and Probability Of Bankruptcy. In general, we advise to go long with undervalued instruments and to sell out overvalued instruments since at some point assets prices and their ongoing real values will submerge.

Edwards Lifesciences Corporation (EW)

The company has Net Profit Margin (PM) of 20.03 % which may suggest that it has a good control over its expenditures, executes well on its competitive polices, or have a solid pricing strategies. This is very large. Likewise, it shows Net Operating Margin (NOM) of 31.38 % which signify that for every $100 of sales it has a net operating income of 0.31. The entity currently falls under 'Large-Cap' category with market capitalization of 36.1B. Edwards Lifesciences shows prevailing Real Value of $147.0 per share. The current price of the firm is $169.97. At this time the firm appears to be overvalued. Macroaxis computes value of Edwards Lifesciences from reviewing the firm fundamentals such as Current Valuation of 36.66B, Profit Margin of 20.03% and Shares Outstanding of 208.5M as well as analyzing its technical indicators and Probability Of Bankruptcy. In general, we advise to go long with undervalued instruments and to sell out overvalued instruments since at some point assets prices and their ongoing real values will submerge. Edwards Lifesciences shows prevailing Real Value of $147.0 per share. The current price of the firm is $169.97. At this time the firm appears to be overvalued. Macroaxis computes value of Edwards Lifesciences from reviewing the firm fundamentals such as Shares Outstanding of 208.5M, Current Valuation of 36.66B and Profit Margin of 20.03% as well as analyzing its technical indicators and Probability Of Bankruptcy. In general, we advise to go long with undervalued instruments and to sell out overvalued instruments since at some point assets prices and their ongoing real values will submerge.

Current 3 Healthcare Recommendations

VolatilityHypeValuationAnalyst ConsensusFinancial LeverageOdds of DistressMacroaxis Advice
CGIX
Not Suitable
CELC
Not Available
Not Available
CDNA
Not Suitable

Competition Technical Indicators

Mean
Deviation
Jensen
Alpha
Sortino
Ratio
Treynor
Ratio
Semi
Deviation
Information
Ratio
Expected
Shortfall
Potential
Upside
Value
At Risk
Maximum
Drawdown
 0.97 (0.24)  0.00 (2.53)  0.00 (0.16)  0.00  1.60 (2.27)  7.76 
 3.97 (0.89)  0.00  0.84  0.00 (0.15)  0.00  7.69 (9.01)  30.84 
 0.00  0.00  0.00  0.00  0.00  0.00  0.00  0.00  0.00  0.00 
 4.01  0.75  0.07 (2.45)  4.76  0.1 (10.50)  12.82 (11.36)  38.21 
 43.29  19.01  0.42 (2.04)  19.74  0.22 (100.94)  127.00 (45.00)  551.43 
 3.90  0.50  0.09 (0.51)  5.14  0.07 (5.02)  6.99 (7.30)  63.46 
 1.86  0.11  0.04 (3.04)  2.57  0.0483 (1.90)  3.64 (3.64)  14.27 
 11.88  2.95  0.15 (2.53)  10.36  0.13 (29.10)  23.08 (18.18)  169.44 
 1.64  0.21  0.05  2.78  2.37  0.07 (3.22)  5.09 (3.84)  16.14 
 3.88 (0.24)  0.00 (0.69)  0.00 (0.0392)  0.00  7.25 (8.42)  33.22 

About Contributor

Ellen Johnson
   Ellen Johnson is a Member of Macroaxs Editorial Board. Ellen covers public companies in North America focusing primarily on valuation and volatility. Six years of experience in predictive investment analytics and risk management. View Profile
This story should be regarded as informational only and should not be considered as solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Ellen Johnson do not own shares of Macroaxis. Please refer to our Terms of Use for any information regarding our disclosure principles.

Did you try this?

Run Portfolio File Import Now

   

Portfolio File Import

Quickly import all of your third-party portfolios from your local drive in csv format
All  Next Launch Module
See also Stocks Correlation. Please also try Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Search macroaxis.com